Echo Trade UPDATE – AVIR

AVIR is a biotech, they had some antiviral phase 2 trial failure news that came out today and the stock is down 65%.  My calls are worth $0.02 now and will cost more to close than the value I can salvage.  I plan to keep holding for now.  If you are in shares you need to make your own decision.  The company says they are pivoting to an alternate drug now.  This kind of news is one of the only ones that trumps the technical patterns.  We can talk about AVIR more tomorrow during the live session.



Daily Profit Publishing and Rob Booker do not provide investment advice. Trading involves a substantial risk of loss and is not suitable for all investors. Many traders fail and you should not trade with money you cannot afford to lose. If you need personal financial advice, consult a financial advisor. We are not licensed to provide you personalized investment advice. Nothing in these communications should be construed as personal investment or financial advice.